Onkologie. 2024:18(Suppl.C):21-24 | DOI: 10.36290/xon.2024.046

Padcev (enfortumab vedotin): a new treatment option for urothelial carcinoma

Lenka Ostřížková
Interní hematologická a onkologická klinika, MOU a LF MU, Brno

The case report presents the initial clinical experience from routine practice with the Padcev (enfortumab vedotin) agent in treating metastatic urothelial carcinoma after failure of a platinum derivative and PD-1/PD-L1 inhibitor.

Keywords: urothelial carcinoma, enfortumab vedotin, EV-301 trial.

Accepted: September 12, 2024; Published: October 2, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ostřížková L. Padcev (enfortumab vedotin): a new treatment option for urothelial carcinoma. Onkologie. 2024;18(Suppl.C):21-24. doi: 10.36290/xon.2024.046.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 2.10.2025

    References

    1. Petrylak DP, Rosenberg JE, Duran I, et al. EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). Journal of Clinical Oncology. 2019;37(7_suppl):TPS497-TPS497. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.